Small Lymphocytic Lymphoma
Information
- Disease name
- Small Lymphocytic Lymphoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04852822 | Active, not recruiting | Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | March 18, 2021 | July 1, 2024 | |
| NCT03410901 | Active, not recruiting | Phase 1 | TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas | April 9, 2018 | October 10, 2024 |
| NCT03088878 | Active, not recruiting | Phase 1/Phase 2 | A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies | January 3, 2018 | August 30, 2024 |
| NCT04666038 | Active, not recruiting | Phase 3 | Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | March 9, 2021 | May 2027 |
| NCT05023980 | Active, not recruiting | Phase 3 | A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | September 23, 2021 | May 2026 |
| NCT01496976 | Active, not recruiting | Phase 2 | Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL | March 30, 2012 | August 4, 2024 |
| NCT03035331 | Active, not recruiting | Phase 1/Phase 2 | Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma | March 27, 2017 | August 2024 |
| NCT02029443 | Active, not recruiting | Phase 1/Phase 2 | ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia | January 30, 2014 | September 6, 2027 |
| NCT04155710 | Active, not recruiting | Phase 1/Phase 2 | Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL | February 19, 2020 | September 2025 |
| NCT02048813 | Active, not recruiting | Phase 3 | Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | February 20, 2014 | December 31, 2024 |
| NCT03162536 | Active, not recruiting | Phase 1/Phase 2 | A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | June 26, 2017 | September 12, 2025 |
| NCT04722172 | Active, not recruiting | Phase 2 | A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL | May 21, 2021 | February 2025 |
| NCT02135133 | Active, not recruiting | Phase 2 | A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL | June 2014 | August 2024 |
| NCT03893682 | Active, not recruiting | Phase 1 | A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas | April 30, 2019 | December 2024 |
| NCT03133221 | Active, not recruiting | Phase 2 | 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation | October 23, 2017 | March 2025 |
| NCT03336333 | Active, not recruiting | Phase 3 | A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL | October 31, 2017 | September 2026 |
| NCT02825836 | Active, not recruiting | Phase 1/Phase 2 | Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects | August 26, 2016 | December 1, 2025 |
| NCT03740529 | Active, not recruiting | Phase 1/Phase 2 | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | November 16, 2018 | January 2028 |
| NCT02296918 | Active, not recruiting | Phase 1 | Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL | December 22, 2014 | September 6, 2027 |
| NCT02337829 | Active, not recruiting | Phase 2 | Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL | January 12, 2015 | April 1, 2026 |
| NCT02339922 | Active, not recruiting | Phase 2 | Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma | May 19, 2016 | January 6, 2031 |
| NCT02514083 | Active, not recruiting | Phase 2 | A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL | December 9, 2015 | October 23, 2028 |
| NCT02518555 | Active, not recruiting | Phase 2 | Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | January 12, 2016 | December 31, 2024 |
| NCT00719888 | Active, not recruiting | Phase 2 | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease | November 18, 2005 | December 22, 2024 |
| NCT01351896 | Active, not recruiting | Phase 2 | Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | November 2, 2011 | December 31, 2024 |
| NCT03737981 | Active, not recruiting | Phase 3 | Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia | January 31, 2019 | June 1, 2027 |
| NCT04624633 | Active, not recruiting | Phase 2 | Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL | December 15, 2020 | January 1, 2030 |
| NCT02629809 | Active, not recruiting | Phase 2 | Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia | March 18, 2016 | March 31, 2025 |
| NCT04542824 | Active, not recruiting | Phase 1/Phase 2 | Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL | August 20, 2020 | December 30, 2024 |
| NCT03701282 | Active, not recruiting | Phase 3 | Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia | February 12, 2019 | May 7, 2028 |
| NCT03078855 | Active, not recruiting | Phase 3 | A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma | September 7, 2017 | September 2024 |
| NCT02756897 | Active, not recruiting | Phase 2 | Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia | July 7, 2016 | July 1, 2024 |
| NCT03422393 | Active, not recruiting | Phase 1 | Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib | May 1, 2018 | August 2028 |
| NCT01578707 | Completed | Phase 3 | A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | June 2012 | October 25, 2018 |
| NCT01611090 | Completed | Phase 3 | A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | September 19, 2012 | January 23, 2019 |
| NCT01650727 | Completed | Phase 1 | A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974) | October 2012 | October 2013 |
| NCT01682616 | Completed | Phase 1 | A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | July 25, 2012 | June 23, 2022 |
| NCT01699152 | Completed | Phase 1 | Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | September 2012 | May 2016 |
| NCT01722487 | Completed | Phase 3 | Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL | March 2013 | May 2015 |
| NCT01724346 | Completed | Phase 3 | Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | August 28, 2012 | August 17, 2023 |
| NCT01754857 | Completed | Phase 2 | Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL | November 12, 2013 | June 30, 2022 |
| NCT00193518 | Completed | Phase 2 | Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | April 2004 | April 2006 |
| NCT01832922 | Completed | Phase 1 | BR in Patients With CLL With Comorbidities and/or Renal Dysfunction | April 2013 | November 28, 2016 |
| NCT04279405 | Completed | Phase 1 | A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies | June 15, 2020 | June 1, 2023 |
| NCT00201682 | Completed | Phase 1/Phase 2 | Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | October 2002 | August 2009 |
| NCT01973387 | Completed | Phase 3 | A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma | October 28, 2013 | August 11, 2017 |
| NCT02004522 | Completed | Phase 3 | A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) | November 2013 | June 2021 |
| NCT02049515 | Completed | Phase 3 | A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07 | December 2013 | June 12, 2020 |
| NCT04030195 | Completed | Phase 1/Phase 2 | Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL | March 24, 2020 | June 24, 2021 |
| NCT02208037 | Completed | Phase 2 | Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) | August 2014 | October 2017 |
| NCT02242045 | Completed | Phase 1 | Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL) | October 1, 2014 | October 17, 2017 |
| NCT03892044 | Completed | Phase 1 | Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma | November 5, 2019 | February 14, 2024 |
| NCT02529813 | Completed | Phase 1 | CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | December 16, 2015 | November 8, 2021 |
| NCT02556931 | Completed | Phase 2 | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies | December 2015 | April 2021 |
| NCT03734016 | Completed | Phase 3 | A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia | November 1, 2018 | February 28, 2024 |
| NCT02639910 | Completed | Phase 2 | Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi | November 2016 | December 2021 |
| NCT02661035 | Completed | Phase 2 | Allo HSCT Using RIC for Hematological Diseases | March 9, 2017 | May 29, 2023 |
| NCT03019055 | Completed | Phase 1 | Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell | October 16, 2017 | August 24, 2021 |
| NCT03096782 | Completed | Phase 2 | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma | October 13, 2017 | September 20, 2022 |
| NCT00290004 | Completed | Phase 1/Phase 2 | Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | November 2005 | February 2007 |
| NCT00439231 | Completed | Phase 2 | Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | February 2007 | November 2010 |
| NCT00535873 | Completed | Phase 2 | Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older | October 2007 | February 2013 |
| NCT00644189 | Completed | Phase 1/Phase 2 | Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma | June 2008 | July 2021 |
| NCT00759603 | Completed | Phase 2 | Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia | September 2008 | July 2014 |
| NCT00801281 | Completed | Phase 3 | First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. | February 2007 | June 25, 2017 |
| NCT00850057 | Completed | Phase 1 | Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | February 2006 | October 2009 |
| NCT00873457 | Completed | Phase 2 | Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | August 2009 | April 2013 |
| NCT00974233 | Completed | Phase 2 | Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL | October 2009 | April 2015 |
| NCT01000753 | Completed | Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma | May 30, 2005 | September 30, 2023 | |
| NCT01002755 | Completed | Phase 2 | Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | January 19, 2010 | January 31, 2018 |
| NCT01105247 | Completed | Phase 1/Phase 2 | Safety of PCI-32765 in Chronic Lymphocytic Leukemia | May 2010 | February 2013 |
| NCT01109069 | Completed | Phase 2 | Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia | June 2010 | April 26, 2019 |
| NCT01113632 | Completed | Phase 2 | Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | July 2010 | August 2016 |
| NCT01117142 | Completed | A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers | June 3, 2010 | July 10, 2020 | |
| NCT01145209 | Completed | Phase 2 | Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL | July 1, 2010 | September 15, 2023 |
| NCT01161511 | Completed | Phase 1 | Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia | September 2010 | January 2013 |
| NCT04858568 | Completed | Immune Responses to COVID-19 Vaccination in Lymphoma Patients | March 11, 2021 | January 31, 2024 | |
| NCT01217749 | Completed | Phase 1/Phase 2 | Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL | December 2010 | May 2014 |
| NCT01231412 | Completed | Phase 3 | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant | November 2010 | June 30, 2017 |
| NCT01239394 | Completed | Phase 2 | Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma | December 2010 | March 2015 |
| NCT01239875 | Completed | Early Phase 1 | Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma | November 2010 | July 17, 2019 |
| NCT01282424 | Completed | Phase 2 | Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas | March 18, 2011 | May 16, 2018 |
| NCT01292135 | Completed | Phase 1 | Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL) | February 2011 | May 2013 |
| NCT01306643 | Completed | Phase 1/Phase 2 | Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma | February 2011 | August 2015 |
| NCT01314014 | Completed | Phase 2 | Imexon for Relapsed Follicular and Aggressive Lymphomas | May 2011 | August 2014 |
| NCT01364363 | Completed | N/A | Unrelated Donor Stem Cell Transplantation | March 2005 | July 2015 |
| NCT01400685 | Completed | Phase 1 | Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL | December 2012 | January 2018 |
| NCT01419691 | Completed | Phase 2 | Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) | September 2011 | September 2015 |
| NCT01484015 | Completed | Phase 1 | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia | February 2011 | October 2012 |
| NCT01497496 | Completed | Phase 2 | Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | January 26, 2012 | March 20, 2020 |
| NCT02910583 | Completed | Phase 2 | Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) | September 28, 2016 | March 27, 2024 |
| NCT00275431 | Completed | Phase 2 | Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies | November 2005 | December 2008 |
| NCT03263637 | Completed | Phase 1 | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | October 24, 2017 | September 30, 2021 |
| NCT01804686 | Enrolling by invitation | Phase 3 | A Long-term Extension Study of PCI-32765 (Ibrutinib) | September 9, 2013 | January 29, 2027 |
| NCT06367374 | Not yet recruiting | Phase 2 | MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL | May 30, 2024 | July 30, 2030 |
| NCT06291220 | Not yet recruiting | Phase 1 | A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | June 2, 2024 | July 21, 2029 |
| NCT05287984 | Not yet recruiting | Phase 2 | Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL | March 22, 2022 | November 29, 2024 |
| NCT06364033 | Not yet recruiting | N/A | Biological and Clinical Efficacy of Shingrix in Patients With CLL | August 2024 | October 2028 |
| NCT05153330 | Recruiting | Phase 1 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL | January 24, 2022 | March 31, 2025 |
| NCT00923507 | Recruiting | Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) | May 29, 2008 | ||
| NCT01787409 | Recruiting | N/A | Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency | March 6, 2013 | March 28, 2025 |
| NCT01962636 | Recruiting | N/A | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases | December 2016 | October 2025 |
| NCT02846623 | Recruiting | Phase 2 | Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome | January 31, 2017 | February 28, 2025 |
| NCT02952508 | Recruiting | Phase 2 | Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia | July 26, 2017 | June 30, 2025 |
| NCT03314974 | Recruiting | Phase 2 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | March 30, 2018 | November 10, 2025 |
| NCT03492125 | Recruiting | Phase 1/Phase 2 | A Study Of The Selective PKC-β Inhibitor MS- 553 | May 25, 2018 | June 15, 2024 |
| NCT03516617 | Recruiting | Phase 2 | Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | September 10, 2018 | March 15, 2026 |
| NCT03960840 | Recruiting | Phase 1/Phase 2 | Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL | June 26, 2019 | June 30, 2027 |
| NCT04269902 | Recruiting | Phase 3 | Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study | March 2, 2021 | October 1, 2028 |
| NCT04282018 | Recruiting | Phase 1/Phase 2 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | May 25, 2020 | December 31, 2025 |
| NCT04494503 | Recruiting | Phase 1/Phase 2 | Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL | August 31, 2020 | December 2025 |
| NCT04505254 | Recruiting | Phase 2 | Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia | August 25, 2020 | June 1, 2024 |
| NCT04545762 | Recruiting | Phase 1 | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma | September 11, 2020 | October 31, 2024 |
| NCT04553692 | Recruiting | Phase 1 | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers | September 23, 2020 | August 2027 |
| NCT04560322 | Recruiting | Phase 2 | Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL | October 19, 2020 | March 1, 2025 |
| NCT04578613 | Recruiting | Phase 3 | ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL | January 8, 2021 | June 30, 2025 |
| NCT04623541 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome | November 25, 2020 | August 2029 |
| NCT04763083 | Recruiting | Phase 1 | First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies | May 14, 2021 | December 2025 |
| NCT04771507 | Recruiting | Phase 1/Phase 2 | A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL) | February 23, 2018 | December 1, 2027 |
| NCT04771572 | Recruiting | Phase 1 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | August 23, 2021 | October 1, 2025 |
| NCT04843904 | Recruiting | Phase 1 | Safe Accelerated Venetoclax Escalation in CLL | April 14, 2021 | June 2, 2030 |
| NCT04867915 | Recruiting | Study on the Diagnosis and Management of CLL in Italy by GIMEMA | October 13, 2021 | October 2026 | |
| NCT04965493 | Recruiting | Phase 3 | A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | September 20, 2021 | January 2027 |
| NCT05006716 | Recruiting | Phase 1/Phase 2 | A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies | September 13, 2021 | March 31, 2028 |
| NCT05020678 | Recruiting | Phase 1 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | August 20, 2021 | December 2038 |
| NCT05031897 | Recruiting | Phase 2 | Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant | October 25, 2021 | October 1, 2024 |
| NCT05147467 | Recruiting | Phase 2 | Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL | December 28, 2021 | December 2024 |
| NCT05183854 | Recruiting | Phase 2 | Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial | January 7, 2022 | January 7, 2027 |
| NCT05254743 | Recruiting | Phase 3 | A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | July 22, 2022 | August 2028 |
| NCT05272813 | Recruiting | Phase 1/Phase 2 | A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL | April 28, 2022 | September 2025 |
| NCT05317936 | Recruiting | Phase 2 | Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax | November 16, 2022 | October 1, 2027 |
| NCT05336812 | Recruiting | Phase 2 | Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia | September 13, 2022 | December 31, 2024 |
| NCT05371808 | Recruiting | Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: | January 27, 2023 | October 1, 2028 | |
| NCT05388006 | Recruiting | Phase 2 | Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | June 15, 2022 | November 15, 2025 |
| NCT05417165 | Recruiting | Phase 2 | Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia | September 29, 2023 | December 31, 2025 |
| NCT05479994 | Recruiting | Phase 2 | Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | October 24, 2022 | August 25, 2027 |
| NCT05602363 | Recruiting | Phase 1 | AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma | August 1, 2023 | September 2027 |
| NCT05677919 | Recruiting | Phase 2 | Pirtobrutinib and Venetoclax Combined With Minimal Residual Disease Detection for Previously Untreated Chronic Lymphocytic Leukemia | January 31, 2023 | July 19, 2025 |
| NCT05694312 | Recruiting | Phase 2 | Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL | November 24, 2023 | November 2026 |
| NCT05718869 | Recruiting | Phase 2 | Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study | May 18, 2023 | October 19, 2025 |
| NCT05805605 | Recruiting | Phase 2 | Allo HSCT Using RIC and PTCy for Hematological Diseases | May 1, 2023 | October 22, 2028 |
| NCT05959694 | Recruiting | Phase 1/Phase 2 | A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . | October 11, 2023 | June 2026 |
| NCT05963074 | Recruiting | Phase 2 | A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia | January 31, 2024 | March 19, 2029 |
| NCT06136559 | Recruiting | Phase 3 | A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) | December 13, 2023 | September 30, 2032 |
| NCT06333262 | Recruiting | Phase 2 | Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia | April 22, 2024 | February 1, 2029 |
| NCT01446900 | Terminated | Phase 2 | R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma | January 2011 | December 2017 |
| NCT02991898 | Terminated | Phase 2 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | February 16, 2017 | June 20, 2019 |
| NCT00942409 | Terminated | Phase 2 | Study of Repeat Intranodal Injections of Ad-ISF35 | June 2009 | July 2014 |
| NCT05107856 | Terminated | Phase 1 | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies | March 22, 2022 | January 19, 2024 |
| NCT04358458 | Terminated | Phase 1/Phase 2 | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas | March 24, 2020 | July 28, 2023 |
| NCT00234481 | Terminated | Phase 1 | Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia | ||
| NCT04504708 | Terminated | Phase 1/Phase 2 | Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies | February 17, 2021 | July 8, 2022 |
| NCT01173679 | Terminated | Phase 2 | Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL | July 2010 | January 2015 |
| NCT01744912 | Terminated | Phase 1 | Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies | November 21, 2012 | February 7, 2014 |
| NCT00022971 | Terminated | Phase 1 | Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia | August 15, 2001 | March 17, 2017 |
| NCT00849524 | Terminated | Phase 2 | Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | January 2009 | July 2014 |
| NCT00100711 | Terminated | Phase 2 | Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | October 2004 | |
| NCT01728207 | Terminated | Phase 1 | Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL | March 2013 | March 2017 |
| NCT03037645 | Terminated | Phase 1/Phase 2 | Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers | April 28, 2017 | August 31, 2020 |
| NCT02877082 | Terminated | Phase 2 | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients | September 2016 | July 2017 |
| NCT02793583 | Terminated | Phase 2/Phase 3 | Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma | May 25, 2016 | July 4, 2022 |
| NCT02784834 | Terminated | Phase 1 | Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL | June 2016 | February 2019 |
| NCT01241786 | Terminated | Phase 2 | Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL | July 2010 | August 2011 |
| NCT03572634 | Terminated | Phase 1/Phase 2 | Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL | June 10, 2019 | January 21, 2020 |
| NCT02258555 | Terminated | Phase 1 | Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma | January 2015 | August 2015 |
| NCT03801525 | Terminated | Phase 2/Phase 3 | Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) | May 16, 2019 | December 20, 2022 |
| NCT03828448 | Terminated | Phase 2 | Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma | July 10, 2019 | May 31, 2022 |
| NCT02258529 | Terminated | Phase 2 | Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma | September 14, 2015 | May 3, 2016 |
| NCT02200848 | Terminated | Phase 1 | Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) | April 2014 | August 1, 2017 |
| NCT01010568 | Terminated | Phase 2 | Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL) | April 2010 | August 2014 |
| NCT02086591 | Terminated | Phase 2 | A Phase II Study of Doxycycline in Relapsed NHL | March 2014 | November 2015 |
| NCT02046928 | Terminated | Phase 2 | Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL) | February 2014 | March 2016 |
| NCT04155840 | Terminated | Phase 2 | Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | January 31, 2020 | March 16, 2021 |
| NCT04176913 | Terminated | Phase 1 | Study of LUCAR-20S in Patients With R/R NHL | December 1, 2020 | December 9, 2021 |
| NCT04682808 | Unknown status | Phase 1 | A Study of FCN-338 in Patients With Chronic CLL/SLL | January 15, 2021 | June 1, 2024 |
| NCT04094051 | Unknown status | Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice | October 1, 2019 | December 31, 2021 | |
| NCT01862445 | Unknown status | Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients | October 2013 | May 2018 | |
| NCT04665115 | Withdrawn | Phase 2 | Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) | November 23, 2020 | July 22, 2022 |
| NCT02623920 | Withdrawn | Phase 2 | Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | December 16, 2015 | May 17, 2017 |
| NCT04694560 | Withdrawn | A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | December 22, 2020 | March 6, 2023 | |
| NCT02576275 | Withdrawn | Phase 3 | A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | December 2015 | November 2016 |
| NCT01163201 | Withdrawn | Phase 1/Phase 2 | T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies | January 2014 | January 2015 |
| NCT03639324 | Withdrawn | Phase 1 | Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL | October 2, 2020 | October 18, 2021 |
| NCT02640833 | Withdrawn | Phase 1 | A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor | July 2016 | February 2021 |
| NCT05521178 | Withdrawn | Cardiotoxicities in Patients Receiving BTKi | May 2024 | January 1, 2028 | |
| NCT03370185 | Withdrawn | Phase 2 | Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma | February 12, 2018 | March 2021 |